Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.

Rampal Rampal, Harrison Harrison, Mesa Mesa, Vannucchi Vannucchi, Shimoda Shimoda, Perkins Perkins, Garcia Garcia, Reiter Reiter, Radinoff Radinoff, Pane Pane, Palandri Palandri, Lomaia Lomaia, Lee Lee, Chuah Chuah, Passamonti Passamonti, Saydam Saydam, Turgut Turgut, Yoon Yoon, Bain Bain, Lam Lam, Jain Jain, Potluri Potluri, Kiladjian Kiladjian